Clinical Trials /

PLX3397 KIT in Acral aNd mucOsal Melanoma

NCT02071940

Description:

KIT (receptor tyrosine kinase) mutations occur in 15% of acral and mucosal melanomas. PIANO is a single arm, phase II, open-label, multicentre study to evaluate the efficacy and safety (plus molecular basis of such effects) of the KIT inhibitor PLX3397 (developed by Plexxikon) in advanced KIT mutated acral and mucosal melanoma. In this trial a total of 24 patients (9 in the first stage and 15 in the second stage) will receive treatment over a 24 month recruitment period. Following consent and successful screening, patients will receive PLX3397 capsules 1000mg/day as monotherapy, and will remain on therapy as long as they are deriving clinical benefit. Patients will be seen every 4 weeks during treatment to monitor response and toxicity. Routine blood tests will be carried out at all visits and pharmacokinetics/pharmacodynamics sampling (1 x 8 milliliter(ml) whole blood sample) will be done pre-dose on Day 1 and Day 15, frozen and stored locally and sent to Plexxikon's vendor for central analysis at the end of the study. Imaging will be carried out every 12 weeks to monitor response. The first 9 patients will also receive two [18F]-fluorodeoxyglucose (FDG) PET scans (baseline and at Day 15). From specific named participating sites, 12 patients will provide additional (optional) consent to take part in translational research. 5 of these patients will have a fresh tumour biopsy taken at baseline, at day 15 and upon disease progression. The same 5 patients plus an additional 7 patients (to give a total of 12 patients) will also donate blood samples at baseline, 2 weeks, 12 weeks and on disease progression for the evaluation of circulating tumour cells and circulating free tumour DNA. All patients will be followed up every 6 months until death or for 12 months after the last patient has discontinued study treatment.

Related Conditions:
  • Melanoma
Recruiting Status:

Recruiting

Phase:

Phase 2

Trial Eligibility

Document

PLX3397 <span class="go-doc-concept go-doc-biomarker">KIT</span> in Acral aNd mucOsal <span class="go-doc-concept go-doc-disease">Melanoma</span>

Title

  • Brief Title: PLX3397 KIT in Acral aNd mucOsal Melanoma
  • Official Title: A Phase II Trial of PLX3397 in the Treatment of KIT Mutated Advanced Acral and Mucosal Melanoma
  • Clinical Trial IDs

    NCT ID: NCT02071940

    ORG ID: 11_DOG12_56

    Trial Conditions

    Malignant Melanoma

    Trial Interventions

    Drug Synonyms Arms
    PLX3397 PLX3397 monotherapy

    Trial Purpose

    KIT (receptor tyrosine kinase) mutations occur in 15% of acral and mucosal melanomas. PIANO
    is a single arm, phase II, open-label, multicentre study to evaluate the efficacy and safety
    (plus molecular basis of such effects) of the KIT inhibitor PLX3397 (developed by Plexxikon)
    in advanced KIT mutated acral and mucosal melanoma.

    In this trial a total of 24 patients (9 in the first stage and 15 in the second stage) will
    receive treatment over a 24 month recruitment period.

    Following consent and successful screening, patients will receive PLX3397 capsules
    1000mg/day as monotherapy, and will remain on therapy as long as they are deriving clinical
    benefit. Patients will be seen every 4 weeks during treatment to monitor response and
    toxicity. Routine blood tests will be carried out at all visits and
    pharmacokinetics/pharmacodynamics sampling (1 x 8 milliliter(ml) whole blood sample) will be
    done pre-dose on Day 1 and Day 15, frozen and stored locally and sent to Plexxikon's vendor
    for central analysis at the end of the study. Imaging will be carried out every 12 weeks to
    monitor response. The first 9 patients will also receive two [18F]-fluorodeoxyglucose (FDG)
    PET scans (baseline and at Day 15).

    From specific named participating sites, 12 patients will provide additional (optional)
    consent to take part in translational research. 5 of these patients will have a fresh tumour
    biopsy taken at baseline, at day 15 and upon disease progression. The same 5 patients plus
    an additional 7 patients (to give a total of 12 patients) will also donate blood samples at
    baseline, 2 weeks, 12 weeks and on disease progression for the evaluation of circulating
    tumour cells and circulating free tumour DNA.

    All patients will be followed up every 6 months until death or for 12 months after the last
    patient has discontinued study treatment.

    Detailed Description

    The PIANO trial is an open-label, single-arm, multicentre phase II trial of PLX3397 in
    advanced acral and mucosal melanoma. All eligible patients will receive PLX3397 1000mg/day
    as monotherapy and will remain on treatment as long as they are deriving benefit (at the
    treating Investigator's discretion).

    The primary objective of this study is to assess the efficacy of PLX3397 by review of the
    number of patients who are progression-free at 6 months. Additional objectives include
    assessing the safety of PLX3397, overall survival and (for a sub-set of patients) biomarker
    research.

    A maximum of 24 eligible patients may be treated in this study. In order to recruit 24
    patients, it is expected that a total of approximately 240 patients will need to be
    consented and screened for the KIT mutation, as only KIT mutant patients are eligible (and
    this is estimated to be 10-15% of this patient population). An interim analysis by the
    Independent Data Monitoring Committee will be done after 9 patients have been recruited and
    if less than 2 out of the 9 patients have demonstrated progression free survival at 6 months
    the trial will be terminated.

    As only KIT mutant patients are eligible for inclusion, the very first step following
    consent is for patients' KIT mutation status to be tested. Only patients who have KIT
    mutations are eligible. Wherever possible, archival tissue samples taken at the time of
    diagnosis will be requested but if a suitable sample is not available or if following
    testing no result is obtained an additional fresh tumour sample would be collected via a
    biopsy. The tissue sample will be sent to specialist laboratories for KIT testing and the
    results of this test take 1-2 weeks. If the patient is found to have a KIT mutation which is
    not associated with PLX3397 resistance, they will return to clinic to complete the following
    study parameters and investigations upto 4 weeks prior to the start of treatment except
    those examinations which are marked with an (*) ;

    - Demographic details

    - Medical and surgical history including discussions of current medications

    - Tumour evaluation according to Response Evaluation Criteria in Solid Tumors (RECIST)
    criteria v1.1 using CT or MRI scans of the thorax, abdomen and pelvis within 28 days of
    scheduled start of treatment

    - Vital signs and standard physical examination (to include blood pressure, pulse,
    temperature, height and weight)*

    - Eastern Cooperative Oncology Group (ECOG) performance status*

    - Laboratory investigations: full blood count, biochemistry (Urea & Electrolytes,
    creatinine, calcium, albumin, liver function tests, lactate dehydrogenase (LDH),
    glucose, phosphate) and clotting screen*

    - Women of childbearing potential will have a urine or serum pregnancy test( within 72
    hours of study entry)

    - Electrocardiograph (ECG)*

    If a patient undergoes a protocol-specified screening procedure as part of Standard of Care
    and the procedure occurs within 4 weeks then this data may be used for screening purposes
    and the test would not need to be repeated.

    If the screening visit confirms that the patient is still eligible to take part in the
    study, they would return to clinic for a "baseline visit" and the following procedures would
    occur:

    - Physical examination (including blood pressure and weight)

    - Electrocardiograph (ECG)

    - ECOG Performance status

    - Laboratory investigations: full blood count, biochemistry (U&Es, creatinine, calcium,
    albumin, liver function tests, LDH, glucose, phosphate) and clotting screen

    - 1 x 8ml whole blood sample (Pharmacodynamics/pharmacokinetics (PK/PD)analysis) to be
    sent to Plexxikon's vendor for central analysis

    - Adverse event (including treatment toxicity) assessments (see section 9.1 for
    definition of an adverse event).

    - Review of concurrent medications

    - PLX3397 prescription

    - PET scan (first 9 patients only)

    - If the baseline visit is < 7 days since screening these investigations will not
    need to be repeated.

    The patient would then return to clinic at day 15, day 29 (week 4), week 8 and then every 4
    weeks in year 1 and every 8 weeks thereafter (until discontinuation of PLX3397). All visits
    have a window of +/- 3 days. The following procedures would be done at these visits:

    - Physical examination (including blood pressure and weight).

    - Electrocardiograph (ECG)

    - ECOG Performance Status (PS)

    - Laboratory investigations: full blood count, biochemistry (U&Es, creatinine, calcium,
    albumin, liver function tests, LDH, glucose, phosphate) and clotting screen.

    - 1 x 8ml whole blood sample (PK/PD analysis) at Day 15 only (sent to Plexxikon's vendor
    for central analysis)

    - Adverse event (including treatment toxicity) assessments until 30 days after
    discontinuation of PLX3397.

    - Review of concurrent medications.

    - Assessment of compliance with study medication.

    - CT or MRI scans of the thorax, abdomen and pelvis at week 12, week 26 and every 12
    weeks thereafter.

    - PET scan after 2 weeks of therapy (day 15 3 days) - first 9 patients only

    When the patient has discontinued the PLX3397 they then enter the follow-up phase of the
    study. Patients will be followed up until death or for 12 months after the last patient has
    discontinued study treatment. Patients can be followed up by telephone call every 6 months
    to assess current status and subsequent therapies. Alternatively follow-up can be in clinic
    especially in the case of complaints which may indicate late toxicity.

    Translational Research

    A subset of patients from named sites (The Christie National Health Service (NHS) Foundation
    Trust and The Royal Marsden NHS Foundation Trust) will also be asked to provide additional,
    optional consent to take part in translational research. 5 patients will have biopsies taken
    at 3 timepoints (baseline, at day 15 and on disease progression) and blood samples taken at
    4 timepoints (baseline, at day 15, week 12 and on disease progression). In addition, a
    further 7 patients will give blood samples only (to give a total of 12 patients giving blood
    samples). Wherever possible translational blood samples will be taken at the same time as
    the standard trial blood samples which confirm that the patient is still eligible for study
    inclusion.

    Trial Arms

    Name Type Description Interventions
    PLX3397 monotherapy Experimental Patients will be given PLX3397 1000mg/day as monotherapy. Patients will remain on treatment as long as they are deriving benefit. This is a single arm study and so there is no comparator arm - all patients receive the same treatment. PLX3397

    Eligibility Criteria

    Inclusion Criteria:

    - Patients with KIT mutated histologically proven advanced mucosal or acral melanoma in
    which the mutation is not known to be associated with PLX3397 resistance

    - Unresectable locally advanced or metastatic disease

    - The presence of one or more clinically or radiologically measurable lesions at least
    10mm in size

    - ECOG performance status 0, 1 or 2

    - Life expectancy greater than 12 weeks

    - Age 18 or greater

    - Women must be postmenopausal (no menstrual period for a minimum of 1 year) or have a
    negative serum pregnancy test on entry in the study (even if surgically sterilised).
    Men and women of childbearing potential must use adequate birth control measures for
    the duration of the study and should continue such precautions for 3 months after
    receiving the last dose of study treatment

    - At least 28 days since major surgery and 7 days since skin/tumour biopsy

    - Serum alanine transaminase (ALT) 2.5 x upper limit of normal (ULN) or serum
    aspartate aminotransferase2.5 x ULN

    - Total serum bilirubin 1.5 x ULN

    - Serum creatinine 1.5 x ULN

    - Haemoglobin 90 g/L, absolute neutrophil count 1.5 x 109/L, platelets 100 x 109/L

    - Prothrombin time (PT) 1.5 x ULN

    - The ability to swallow and retain oral medication

    - The capacity to understand the patient information sheet and the ability to provide
    written informed consent

    - Willingness and ability to comply with scheduled visits, treatment plans, laboratory
    tests and other study procedures

    Exclusion Criteria:

    - Intracranial disease, unless there has been radiological evidence of stable
    intracranial disease > 6 months. In the case of a solitary brain metastasis, evidence
    of a disease-free interval of at least 3 months post surgery. All patients previously
    treated for brain metastases must be stable off corticosteroid therapy for at least
    28 days

    - Women who are pregnant, nursing, or planning pregnancy within 6 months after the last
    treatment

    - Men who plan to father a child within 3 months of the last treatment

    - Use of any investigational drug within 30 days prior to screening

    - Significant cardiac disease including patients who have or who are at significant
    risk of developing prolongation of corrected QT interval (QTc)

    - Severe and/or uncontrolled medical disease

    - Known chronic liver disease

    - Known HIV infection

    - Previous radiotherapy to 25% or more of the bone marrow and/or radiation therapy in
    the 4 weeks prior to study entry

    - Prior exposure to a KIT inhibitor

    - Patients with KIT mutations that are known to be associated with PLX3397 resistance

    - Use of Chinese or herbal medication

    - Any malabsorption syndrome (i.e. partial gastrectomy, small bowel resection, crohn's
    disease or ulcerative colitis)

    Minimum Eligible Age: 18 Years

    Maximum Eligible Age: N/A

    Eligible Gender: Both

    Primary Outcome Measures

    Efficacy of PLX3397

    Secondary Outcome Measures

    Response rate

    Overall Survival

    Safety of PLX3397

    Mechanism of response and resistance to PLX3397

    Trial Keywords

    Acral Melanoma subtypes

    Mucosal Melanoma subtypes